Response to ‘Adynamic Bone Disease and MICS’  by Kalantar-Zadeh, K. & Kopple, J.-D.
Response to ‘Adynamic Bone
Disease and MICS’
Kidney International (2007) 71, 1327; doi:10.1038/sj.ki.5002264
We appreciate the important thoughtful points raised
by Dr Heaf1 regarding adynamic bone disease (ABD).
ABD may indeed be a secondary phenomenon and a
consequence of the malnutrition–inflammation complex
syndrome (MICS), which is also associated with hypo-
albuminemia, increased serum levels of proinflammatory
cytokines, protein–energy wasting, and poor outcome in
maintenance dialysis patients.2 A recent study in 44
chronic peritoneal dialysis patients showed that low serum
albumin was associated with ABD.3 Although we are not
aware of any study that indicates a direct causal effect of
inflammation on ABD in chronic kidney disease, in vitro
parathyroid hormone (PTH) secretion is suppressed by
interleukin-6,4 a strong proinflammatory cytokine that is
associated with poor outcome in maintenance-dialysis
patients. Interleukin-1 beta (IL-1b), another proinflamma-
tory cytokine, may also suppress PTH secretion. In another
in vitro study, PTH secretion from cultured parathyroid
tissue slices was significantly inhibited in media containing
IL-1b.5 This effect may be mediated through the specific
IL-1 receptors that upregulate the calcium-sensing receptor
mRNA leading to apparent low bone turnover.5 Indeed in
the foregoing study, the inhibitory effect of IL-1b could be
counteracted by the IL-1 receptor antagonist (IL-1ra),5
indicating that the inflammation-induced suppression of
PTH can potentially be overcome by treatment of MICS in
individuals with chronic kidney disease. Hence, interven-
tions that can improve hypoalbuminemia and kidney
disease wasting by correcting malnutrition and/or by
mitigating inflammation, for example, via IL-1ra anakinra,
may be more promising approaches for the management of
ABD rather than decreasing the dose of or withholding
activated vitamin D analogs.
In our study, the MICS could indeed explain a large
portion of the association between low PTH and increased
death rate. However, in our epidemiologic study, inflam-
matory markers and cytokines were not measured. Hence,
controlling for MICS was suboptimal, which may explain
the existence of the residual association between low PTH
and death after multivariate adjustment. Moreover, many
patients with low PTH did not receive paricalcitol,6 which
may be another explanation for high mortality in this
group. Nevertheless, any dose of paricalcitol is associated
with better survival compared to no paricalcitol adminis-
tration, including in those with low PTH levels.6 As Dr
Heaf suggested, we plan to perform additional subgroup
analyses to examine more carefully the association of ABD
and MICS in maintenance-dialysis patients.
K Kalantar-Zadeh has received honoraria from Abbott
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Don’t be so BOLD: Potential
limitations in the use of BOLD MRI
for studies of renal oxygenation
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To the Editor: Blood oxygen level-dependent contrast
magnetic resonance imaging is used for studies of intrarenal
oxygenation1 and has been touted as a useful non-invasive
diagnostic tool in renal medicine. The validity of this
technique as an indicator of parenchymal oxygenation,
however, relies on the assumption that tissue oxygenation
varies with blood oxygenation. We recently found that in
both rabbits and rats renal cortical and medullary tissue pO2
can remain remarkably stable in the face of changes in renal
blood flow,2 even if renal oxygen consumption does not
change.3 We also observed increased renal venous blood
oxygen content with increasing renal blood flow, despite
stable tissue pO2.
3 These observations support the concept
that diffusional shunting of oxygen from arteries to veins
increases with increased renal blood flow and so contributes
to dynamic regulation of renal oxygenation.3 The possibility
that similar mechanisms operate in the human kidney raises
concerns over the reliability of clinical assessment of renal
tissue oxygenation using blood oxygen level-dependent
magnetic resonance imaging. Our data indicate that changes
in the oxygen level of blood in the renal circulation, as
evidence by altered renal venous pO2, do not necessarily
reflect changes in tissue pO2. The possibility that kidney
vascular oxygenation and tissue oxygenation may vary
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